Press "Enter" to skip to content

IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer – West Plains Daily Quill

admin 0

IMFINZI® (durvalumab) Improves Overall Survival at Interim Analysis in the Phase III CASPIAN Trial in 1st-Line Extensive-Stage Small Cell Lung Cancer  West Plains Daily Quill

WILMINGTON, Del.–(BUSINESS WIRE)–Jun 27, 2019–. AstraZeneca today announced positive overall survival (OS) results from the Phase III CASPIAN trial …

“liver cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *